Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc.
33 months ago

Celsion rebrands to Imunon to reflect immunotherapy, COVID-19 vaccine ambitions ... As it continues to push its DNA-based interleukin-12 (IL-12)...
33 months ago

Imunon, Inc. (NASDAQ:IMNN), a pharmaceutical company based in Lawrenceville, NJ, with a market capitalization of $6.17 million, has formally...
1 month ago

The Company's completed Phase Ib dose-escalating OVATION I Study with GEN-1 in Stage III/IV ovarian cancer patients showed positive results in progression-free...
63 months ago

Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control...
52 months ago

Celsion Corporation announced that fast track designation was granted to their immunotherapy, GEN-1, to treat patients with advanced stage...
52 months ago

FDA Grants Fast Track Status to Celsion's GEN-1 for Advanced Cancer ... In News. ... Click here to subscribe to the Ovarian Cancer News Today...
52 months ago

The team has applied for a license under the name Celsion Bank with the Financial Markets Authority (FMA) in Liechtenstein.
12 months ago

This marks a major initiative for Imunon CEO Dr. Corinne Le Goff, who joined the company after serving as chief commercial officer at...
33 months ago

Treating breast cancer with a type of heat therapy derived from MIT radar research can significantly increase the effectiveness of chemotherapy.
210 months ago